Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines

British Journal of Cancer

Volumn 88, Issue 8, 2003, Pages 1327-1334

  Chauhan, S S ^a,c   Liang, X J ^a   Su, A W ^a   Pai Panandiker, A ^a   Shen, D W ^a   Hanover, J A ^b   Gottesman, M M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cisplatin resistance; EGF binding; Endosomal lysosomal acidification; Fluid phase receptor mediated endocytosis; Pseudomonas exotoxin

Indexed keywords

BAFILOMYCIN A1; CARBOPLATIN; CATHEPSIN L; CISPLATIN; CYTOTOXIC AGENT; DEXTRAN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAVY METAL; HORSERADISH PEROXIDASE; METHOTREXATE; PSEUDOMONAS EXOTOXIN; TRICHLOROACETIC ACID;

ACIDIFICATION; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ISOLATION; CROSS RESISTANCE; DRUG ACCUMULATION; ENDOCYTOSIS; HUMAN; HUMAN CELL; LYSOSOME; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SQUAMOUS CELL CARCINOMA;

BIOLOGICAL TRANSPORT; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; EPIDERMAL GROWTH FACTOR; HORSERADISH PEROXIDASE; HUMANS; LYSOSOMES;

EID: 0038485704     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600861     Document Type: Article

References (45)

1. Amano F, Gottesman MM, Pastan I (1998) Epidermal growth factor-dependent growth of human KB cells in a defined medium and altered growth factor requirements of KB mutants resistant to EGF - Pseudomonas exotoxin conjugates. J Cell Physol 26: 502-508
2. 125I-labelled human epidermal growth factor: binding internalization, degradation in human fibroblasts. J Cell Biol 71: 159-171
3. Chauhan SS, Ray D, Kane SE, Willingham MC, Gottesman MM (1998) Involvement of carboxy-terminal amino acids in the secretion of human lysosomal protease cathepsin L. Biochemistry 37: 8584-8594
4. Chu G (1994) Cellular responses to cisplatin. The role of DNA binding proteins and DNA repair. J Biol Chem 269: 787-790
5. Das M, Chauhan SS, Misra VS, Sanger JM, Sanger JW, Roy-Chaudhary S (1989) Aberrant post endocytotic fate of a 34-kDa molecular mass growth factor from human trophoblasts. Cancer Res 4: 2761-2765
6. DeFeudis P, D'Incalci M, Broggini M (1996) Block of bcr - abl expression and induction of apoptosis by cis-platinum in human chronic myeloid leukemia cell line. Apoptosis 1: 161-166
7. Fanidi A, Harrington EA, Evan GI (1993) Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359: 554-556
8. Fink D, Aebi S, Howell SB (1998) The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4: 1-6
9. Godwin AK, Meister A, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074
10. Gosland S, Lum B, Schimmelpfennig J, Baker J, Doukas M (1996) Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16: 16-39
11. Hettinga JVE, Konings AW, Kampinga HH (1997) Reduction of cellular cisplatin resistance by hyperthermia - a review. Int J Hypertherm 13: 439-457
12. Husain A, He G, Venkatraman ES, Spriggs DR (1998) BRCA 1 up-regulation is associated with repair mediated resistance to cis-diaminedichloroplatinum(II). Cancer Res 58: 1120-1123
13. Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr 1 in yeast and mammals. Proc Natl Acad Sci USA 99: 14298-14302
14. Johnson SW, Shen DW, Pastan I, Gottesman MM, Hamilton TC (1996) Cross resistance, cisplatin accumulation, and platinum - DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. Exp Cell Res 226: 133-139
15. Katano K, Kondo A, Safaei R, Hoher A, Samimi G, Mishima M, Kuo YM, Rochdi M, Howell SB (2002) Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62: 6559-6565
16. Kelly SL, Basu A, Ticher BA, Hacker MP, Hammer DH, Lazo JS (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813-1815
17. Kondo Y, Kuo SM, Watkin SC, Lazo JS (1995) Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res 55: 474-477
18. Lai SL, Hwang J, Perng RP, Whang-Peng J (1995) Modulation of cisplatin resistance in acquired-resistant non small cell lung cancer cells. Oncology Res 7: 31-38
19. Laurencott CM, Andrews PA, Kennedy KA (1995) Inhibitors of intracellular pH regulation induce cisplatin resistance in EMT 6 mouse mammary tumor cells. Oncol Res 7: 363-369
20. Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR (1992) Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer 66: 1109-1115
21. Lowe SW, Ruley HE, Jacks T, Housman DE (1993) p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 975-967
22. Lyall RM, Hwang J, Cardarelli C, FitzGerald D, Akiyama S, Gottesman MM, Pastan I (1987) Isolation of human KB cell lines resistant to epidermal growth factor -Pseudomonas exotoxin conjugates. Cancer Res 47: 2961-2966
23. Maxfield FR, Yamashiro DJ (1991) Acidification of organelles and the intracellular sorting of proteins during endocytosis. In Intracellular Trafficking of Proteins, Steer CJ, Hanover JA (eds) pp 157-182. Cambridge, UK: Cambridge University Press
24. Melikova MS, Blagoveshchenskaya AD, Nikolsky NN, Kornilova ES (2001) Influence of vacuolar proton pump inhibitor bafilomycin A1 on intracellular processing of receptor-mediated and fluid phase endocytosis markers. Abstract in 41st American Society for Cell Biology Annual Meeting, Washington DC, 8-12 December pp 344a-345a
25. Miesenbock G, De Angelis DA, Rothman JE (1998) Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins. Nature 394: 192-195
26. Minn AJ, Rudin CM, Boise LH, Thompson CB (1995) Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86: 1903-1910
27. Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA, Harrap KR (1992) Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro-(cyclohexylamine)-platinum(IV) (JM1221) in human ovarian carcinoma cell lines. Cancer Res 52: 6188-6193
28. Moorehead RA, Singh G (2000) Influence of proto-oncogene c-fos on cisplatin sensitivity. Biochem Pharmacol 59: 337-345
29. Moscow JA, Cowan KH (1998) Multidrug resistance. J Natl Cancer Inst 80: 14-20
30. Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M, Izumi H, Nakamura T, Matsuo K, Yamada Y, Kohno K (2001) Elevated expression of vacuolar protein pump genes and cellular pH in cisplatin resistance. Int J Cancer 93: 869-874
31. Naredi P, Heath DD, Enns RE, Howell SB (1994) Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line. Cancer Res 52: 6464-6468
32. Niedner H, Christen R, Lin X, Howell SB (2001) Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 60: 1153-1160
33. Olsnes S, Sandvig K (1988) How protein toxins enter and kill cells. In Immunotoxins, Frankel AE (ed) pp. 39-73. Dordrecht, the Netherlands: Kluwer Academic Publishers
34. Ozols RF, Williams SD (1989) Testicular cancer. Curr Prob Cancer 13: 287-335
35. Pastan I, Chaudhary V, Fitgerald DJ (1992) Recombinant toxins as novel therapeutic agents. Annu Rev Biochem 61: 331-354
36. Perez RP (1998) Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542
37. Salminen A, Gottesman MM (1990) Inhibitor studies indicate that active cathepsin L is probably essential to its own processing in cultured fibroblasts. Biochem J 272: 39-44
38. Shen DW, Akiyama S-I, Schoenlein P, Pastan I, Gottesman MM (1995) Characterization of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer 71: 676-683
39. 14C-carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiology 183: 108-116
40. Shen DW, Pastan I, Gottesman MM (1998) Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 58: 268-275
41. Simonian PL, Grillot DAM, Nunez G (1997) Bcl-2 and BcL-XL can differentially block chemotherapy-induced cell death. Blood 90: 1208-1216
42. West MA, Bretscher MS, Watts C (1989) Distinct endocytotic pathways in epidermal growth factor-stimulated human carcinoma A431 cells. J Cell Biol 109: 2731-2739
43. Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y (1991) Bafilomycin A, a specific inhibitor of vacuolar-type H+-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem 266: 17707-17712
44. Zaman GJ, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Planlusma C, Oude Elferink RP, Baas F, Borst P (1995) Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 92: 7690-7694
45. Zhen M, Link Jr CJ, O'Connor PM, Reed E, Parker P, Howell SB, Bohr VA (1992) Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12: 3689-3698